Surviving Acute Liver Failure


April 26, 2023



ALF is profoundly higher in those who have coagulopathy [ the body’s inability to coagulate] and/or renal failure. Studies show it takes at least 10 grams of paracetamol to induce ALF, however, the norm is over 30 grams.

Clinical acute liver failure is a progressive response to multi-organ failure. The severity depends upon the metabolic consequences of the loss of liver function. Systemic effects of toxins resulting in a necrotic liver and the rate of failure play a role in the severity and prognosis of the outcome.

Encephalopathy [condition of damage or malfunction of the brain] caused by severe liver impairment results in the patient having abnormal mental activity, drowsiness, euphoria, confusion, or deep coma. Cerebral involvement from ALF occurs in 75 to 80 % of patients, with grade 4 encephalopathy as the primary cause of death.

Treating edema:

The use of Mannitol or other diuretics to reduce excess fluid in the body [liver, cerebral, kidney] has been shown to improve survival rates with ALF patients with grade 4 encephalopathy; reducing the excess brain fluid and reducing ICP [intracerebral pressure].

N-acetylcysteine [NAC] has been shown to be a benefit. While some may believe it has no direct effect on ICP, helping to reduce the edema in the brain through increased cerebral blood flow could reduce the fluid. As a free radical scavenger NAC can provide further benefits.

Cream of Tartar [potassium bitartrate] a by-product of the fermentation process in wine making, used as a stabilizer in food products was said to be used in the 18th century to reduce edema in patients suffering from ALF. Giving the patient a small amount, 1/8 to 1/4 teaspoon, was shown to reduce the edema.

Patients with ALF are prone to infections and it can be the ultimate killer. Studies have found isolated microorganisms were predominately gram-positive bacteria, while other studies have shown gram-negative [especially E.coli ] being the most predominant, followed by Staphylococcus. Still, there are fungal infections, a third being Candida.

Hypoglycemia is the most common metabolical dysfunction seen in ALF patients due to the loss of glucose caused by loss of liver cell function. Giving the patient glucose as a prophylaxis or treatment of hypoglycemia benefits the patient but does not seem to change or benefit the outcome directly.

Pulmonary complications including edema, pneumonia, or tracheobronchitis are most common and appear to be caused by metabolic and toxic factors increased due to liver and/or organ failures brought on by ALF. An increased susceptibility to infections is a leading cause of these complications.

ALF, despite all mainstream medical advancements in intensive care and developments in new mainstream treatment modalities, remains a condition with high mortality. Bioartificial liver support or hepatocyte transplantation [ hepatocytes being 80 percent of the liver are transplanted to create a new liver mass], may be options to change the outcomes of liver failure in the future.

In conclusion, liver failure that can and does quickly escalate into acute organ failure, organ edema and encephalopathy remains a condition with a poor prognosis.  The overindulgence of medications like paracetamol for pain and inflammation needs addressing. Furthermore, the wide use of prescribed medications for a sundry of complaints, as well the accepted use of chemotherapy drugs for treating cancer and other autoimmune disease may well be the predominant cause of ALF. Cancer patients commonly have liver involvement due to metastases. Such impairment sets up the liver for failure when chemotherapy drugs stress and damage the liver. ALF is a common cause of mortality in cancer patients. We know the use of non-toxic treatments can greatly change the outcome yet are not recognized or acknowledged by mainstream practitioners. Using anti-bacterial, anti-viral, and anti-fungal modalities for infections benefits the outcome. We have stopped the decline in ALF cancer patients using Paradigm Research’s Cell -F- Defense having pulmonary infections, edema using Cream of Tartar treatment, and the Triple Liver Treatment to help restore function to the liver. Surviving ALF is possible, that we know.

Contact Jesicha’s Hope [ ] to discuss further your interest in minimizing ALF mortality. We do not treat, or offer medical advice but give tools and information to heal oneself.  We believe the body knows how to heal. Give it the tools and eliminate toxins then watch healing begin.



Williams R. New directions in acute liver failure. J R Coll Physicians Lond 1994

Ellis A, Wendon J. Circulatory, respiratory, cerebral, and renal derangements in acute liver failure: Pathophysiology and management. Semin Liver Dis 1996

Canalese J, Gimson AE, Davis C, Mellon PJ, Davis M, Williams R. Controlled trial of dexamethasone and mannitol for cerebral edema of fulminant hepatic failure. Gut 1982

Keays R, Harrison PM, Wendon J, et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. Br Med J 1991

Canalese J, Gimson AE, Davis C, Mellon PJ, Davis M, Williams R. Controlled trial of dexamethasone and mannitol for cerebral edema of fulminant hepatic failure. Gut 1982

Laggner A, Kleinberger G, Haller J, Czembirek H, Drumi W, Lenz K. Pulmonale Komplikationen bei Coma hepaticum. Leber Magen Darm 1982

Pathophysiology and management of acute liver failure E. Pyleris, G. Giannikopoulos, K. Dabo, ANNALS OF GASTROENTEROLOGY 2010








Copyright © Jesicha's Hope Library.2012 -2023

updated January 2023 

DISCLAIMER: Jesicha's Hope makes no representations or warranties, express or implied, as to the accuracy, completeness, usefulness or and other reason not mentioned of Jesicha's Hope website, social comments or any other media or method of communication by Jesicha's Hope, any content and to the extent allowed by law; Jesicha's Hope expressly disclaims all warranties, expressed or implied, including without limitation implied warranties of merchantability and fitness for any purpose whatsoever. You shall assume all risk associated with the use of Jesicha's Hope website and of any content or communication, including but not limited to any other type of communication not listed herein; Jesicha's Hope does not assume any risk and shall have no liability whatsoever for your use of the website or any content therein. Jesicha's Hope will have the right at any time to change content and Jesicha's Hope is not responsible for any incorrect or inaccurate content.  The use of the Jesicha's Hope website or any of its content does not create or express or imply any doctor/patient relationship with any doctor, clinic, hospital or other facility mentioned or included in content herein. Jesicha's Hope is not liable for contacting or follow up timeliness. In no event will Jesicha's Hope be liable to you in any manner whatsoever for any decision made by you, or action made by you, or non-action taken by you based on any content herein

FOR ALL UNITED STATES VISITORS: FDA Required Disclaimer For Sites That Do Not Endorse Chemotherapy:

This web site is for educational purposes only. It is not intended as a substitute for the diagnosis, treatment and advice of a qualified licensed professional. This site offers people medical information and tells them their alternative medical options, but in no way should anyone consider that this site represents the “practice of medicine.” This site assumes no responsibility for how this material is used. Also note that this website frequently updates its contents, due to a variety of reasons, therefore, some information may be out of date. The statements regarding alternative treatments for cancer have not been evaluated by the FDA.